PMGC Holdings Shares Are Up Today: What's Going On?

Zinger Key Points

PMGC Holdings Inc. ELAB shares are trading higher Friday after the company announced that its subsidiary, Northstrive Biosciences, will present at an upcoming UCLA symposium on anti-obesity treatments.

What To Know: The presentation will highlight Northstrive’s lead asset, EL-22, a first-in-class engineered probiotic designed to preserve muscle mass in patients undergoing weight-loss treatments, including GLP-1 receptor agonists.

The symposium, organized by UCLA’s Metabolism Theme at the David Geffen School of Medicine, will bring together leading clinicians, researchers and drug developers to address the challenges posed by weight loss therapies, particularly muscle and bone loss associated with GLP-1 receptor agonists.

Studies indicate that 30-50% of body weight lost through GLP-1 therapy consists of lean muscle mass. This is a significant issue that lacks an approved treatment. Northstrive’s EL-22 aims to fill this gap by offering a potential combination therapy to mitigate muscle loss.

The announcement may have sparked investor enthusiasm, as the company’s participation in the symposium is expected to provide exposure to key stakeholders in the obesity treatment sector, including potential investors and pharmaceutical partners.

Price Action: PMGC shares were up 61.1% at $3.19 at the time of writing, according to Benzinga pro.

Read Next:

Image Via Shutterstock.

ELAB Logo
ELABPMGC Holdings Inc
$2.293.15%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
0.08
Price Trend
Short
Medium
Long
Got Questions? Ask
Which biotech companies may partner with Northstrive?
How will weight-loss therapies impact pharma stocks?
Could EL-22 become a market leader in obesity treatments?
What are the growth prospects for probiotic therapies?
Which healthcare ETFs could benefit from this innovation?
How might investor sentiment shift towards obesity treatments?
What implications does this have for GLP-1 drug manufacturers?
How will clinical partnerships affect Northstrive's expansion?
Are there risks for companies in the obesity sector?
Which investors are likely to show interest in EL-22?
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...